HIV/AIDS Treatment Trends and Progress: Where Do We Stand Today?
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Address: 72 Steel Road Spartan , Kempton Park ,South Africa
Tel: +27 11975 0654
Sandoz, the generic pharmaceuticals division of the Novartis Group, is a global leader in the rapidly growing generics industry. With quality going back to its roots in the 19th century, Sandoz has a strong global presence covering 90% of the world’s population. We are committed to providing healthcare products and services of a consistently high standard, worldwide. We believe that consistent and reliable quality is what sets us apart from our competition, by offering customers the safety and efficacy associated with reference medicines, at lower cost.
At Sandoz we make far more than just traditional off-patent medicines. We develop and manufacture a wide range of difficult-to-make medicines, ranging from complex delivery systems for standard generics through to modern biopharmaceutical medicines (biosimilars).
Adhering to one, uniform standard, Sandoz South Africa supplies a comprehensive range of medicines for just about every therapeutic area, from Cardiovascular, Anti-Infectives, CNS, Analgesics, and the challenging field of TB.
Our core business lies in the development, production and distribution of high-quality, affordable generic medicines. We offer approximately 1 000 generic compounds worldwide and are a leading provider of differentiated, value-added products, including state-of-the-art biosimilars, injectables, inhalers and transdermal patches.
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential…
The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one…
In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of…
During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in…
As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam…
Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as…
Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the…
Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a…
Some of the top pharma news coming out of South Africa including Afrigen’s partnership with US National Institutes of Health (NIH), BioNTech’s efforts to bring an mRNA start-to-finish vaccine manufacturing network…
See our Cookie Privacy Policy Here
